总部位于巴黎的生物技术公司Aqemia近日获得了3000万欧元的A轮追加融资，该公司致力于利用生成式AI和量子技术发现和设计新药物。此次融资由Wendel Growth领投，现有投资者法国VC Eurazeo、公共银行Bpifrance以及Elaia参投。至此，Aqemia的A轮融资总额已达6000万欧元。
Aqemia公司开发了一种人工智能驱动的技术，该技术能加速分子的发现和设计，这些分子有望成为治疗多种疾病的药物。该公司利用这一技术，已成功筹集了3000万欧元的追加资金，以加速其在药物研发领域的创新。
此次融资将助力Aqemia进一步优化其人工智能驱动的药物研发平台，缩短药物研发周期，降低研发成本。此外，这笔资金还将用于扩大公司规模，招聘更多优秀人才，以及深化与合作伙伴的合作。
英文翻译：
News title: AI-powered drug discovery startup Aqemia raises €30 million Series A extension
Keywords: AI, drug discovery, biotechnology, financing
News content:
Paris-based biotechnology company Aqemia has raised €30 million in a Series A extension round to continue developing its AI-powered approach to drug discovery and design. The round was led by Wendel Growth with participation from existing investors French VC firm Eurazeo, public bank Bpifrance, and Elaia. To date, Aqemia’s Series A financing has reached a total of €60 million.
Aqemia has developed an AI-driven technology that accelerates the discovery and design of molecules that could become drugs to treat various diseases. The company has raised €30 million in additional funding to speed up its innovation in drug development.
The financing will enable Aqemia to further optimize its AI-powered drug discovery platform, accelerate the development cycle, and reduce research and development costs. The funds will also be used to expand the company’s scale, hire more talented individuals, and deepen partnerships with collaborators.
【来源】https://sifted.eu/articles/aqemia-60m-series-a
Views: 2